Home   Therapie   Ärzte   NETZWERK   Workshops   Kontakt   Mitglieder-Login   Facebook  










Newsletter?

Click here!

29/05 2015

Veröffentlichungen

1. Ablon G, Rotunda AM: Treatment of lower eyelid fat pads using phosphatidylcholine: clinical trial and review. Dermatol. Surg. 2004; 30: 422-7

2. Adelson H: Management of side effects and adverse reactions from injection of phosphatidylcholine. Am. J. Mesotherapy 2006; 5: 16-7

3. Atiyeh BS, Ibrahim AE, Dibo SA: Cosmetic mesotherapy between scientific evidence, science fiction, and lucrative business. Aesthet. Plast. Surg. 2008; 32: 842-9

4. Avelar JM: Comment on “refinement of technique in injection lipolysis based on scientific studies and clinical evaluations”. Clin. Plast. Surg. 2009; 36: 211-3

5. Bates B: ‘Fat dissolving’ substance injects CCs of controvery: despite growing U.S. interest, Lipostabil’s safety remains uncertain, experts warn. Skin & Allergy News 2003; 34: 1

6. Baumann L: Cosmeceutical critique: phosphatidylcholine. Skin & Allergy News 2003; 34: 24-5

7. Bechara FG, Mannherz HG, Jacob M, Mazur AJ, et al: Induction of fat cell necrosis in human fat tissue after treatment with phosphatidylcholine and deoxycholate. JEADV 2012; 26: 180-5

8. Bechara FG, Georgas D, Sand M, Tomi N, et al: Incapsulated fat necrosis after lipolysis of the calf with phosphatidylcholine. Dermatology 2008; 216: 180-1

9. Bechara FG, Skrygan M, Kreuter A, Altmeyer P, et al: Cytokine mRNA levels in human fat tissue after injection lipolysis with phosphatidylcholine and deoxycholate. Arch. Dermatol. 2008; 300: 455-9

10. Bechara FG, Sand M, Hoffmann K, Sand D, et al: Fat tissue after lipolysis of lipomas: a histopathological and immunohistochemical study. J. Cutan. Pathol. 2007; 34: 552-7

11. Bechara FG, Sand M, Sand D, Rooterdam S, et al: Lipolysis of lipomas in patients with familial multiple lipomatosis: an ultrasonography-controlled trial. J. Cutan. Med. Surg. 2006; 10: 155-9

12. Bechara FG, Sand M, Altmeyer P, Hoffmann K: Intralesional lipolysis with phosphatidylcholine for the treatment of lipomas: pilot study. Arch. Dermatol. 2006; 142: 1069-70

13. Bellman B: Phosphatidylcholine reaction. Skin & Allergy News 2003; 34: 12

14. Brown SA: Commentary on: Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet. Surg. J. 2013; 33: 409-10

15. Brown SA: The science of mesotherapy: chemical anarchy. Aesthet. Surg. J. 2006; 26: 95-8

16. Bryant R: Controversial mesotherapy: could it be the next botox? Dermatol. Times 2004; 25: 1

17. Chase CC: Common complications and adverse reactions in a mesotherapy practice. Am. J. Mesotherapy 2006; 1: 14-5

18. Chung SJ, Chung HL, Ho SL, Sung TK, et al: The role of phosphatidylcholine and deoxycholic acid in inflammation. Life Sci. 2014, dx.doi.org/10.1016/j.lfs.2014.05.013

19. Co AC, Abad-Casintahan MF, Espinoza-Thaebtharm A: Submental fat reduction by mesotherapy using phosphatidylcholine alone vs. phosphatidylcholine and organic silicium: a pilot study. J. Cosm. Dermatol. 2007; 6: 250-7

20. De Paula Mesquita T, de Almeida HL, de Paula Mesquita MC: Histological resolution of naevus lipomatosus superficialis with intralesional phosphatidylcholine. JEADV 2009; 23: 714-5

21. Dobrodin A: The treatment for eye pads revealed. Am. J. Mesotherapy 2006; 1: 16-7

22. Doerr TD: Lipoplasty of the face and neck. Curr. Opin. Otolaryngol. Head Neck Surg. 2007; 15: 228-32

23. Duncan DI: Commentary on: Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet. Surg. J. 2013 33: 411-3

24. Duncan DI: Letter to the editor – Response to “injection lipolysis with phosphatidylcholine and deoxycholate”. Aesthet. Surg. J. 2013; 33: 1073-5

25. Duncan D, Rotunda AM: Injectable therapies for localized fat loss: state of the art. Clin. PLast. Surg. 2011; 38: 489-501, vii

26. Duncan D, Rubin JP, Golitz L, Badylak S, et al: Refinement of technique in injection lipolysis based on scientific studies and clinical evaluation. Clin. Plast. Surg. 2009; 36: 195-209,v-vi; discussion 211-3

27. Duncan DI, Palmer M: Fat reduction using phosphatidylcholine/sodium deoxycholate injections: standard of practice. Aesthetic Plast. Surg. 2008; 32: 858-72

28. Duncan DI: The role of phosphatidylcholine in non-surgical body contouring. In: Aesthetic Mesotherapy and Injection Lipolysis in Clinical Practice, edt. by Sh.Madhère. Replika press Pvt, Ltd./India 2007: chapter 8: 61-75

29. Duncan DI, Chubaty R: Clinical safety data and standards of practice for injection lipolysis: a retrospective study. Aesthet. Surg. J. 2006; 26: 575-85

30. Duncan DI, Hasengschwandtner F: Lipodissolve for subcutaneous fat reduction and skin retraction. Aesthet. Surg. J. 2005; 25: 530-43

31. Friedland JA: Comment on “mesotherapy and injection lipolysis”. Clin. Plast. Surg. 2009; 36: 193

32. Frisari P, Pinto R: Mesosculpt with phosphatidylcholine. Am. J. Mesotherapy 2006; 6: 9

33. Fritz K, Tiplica G-S: Kosmet. Med. 2011; 32: 280-6

34. Göller A: Lipolyse in der plastischen Chirurgie. Dissertation, Ulm 2011

35. Gupta A, Lobocki C, Singh S, Robertson M, et al: Actions and comparative efficacy of phosphatidylcholine formulation and isolated sodium deoxycholate for different cell types. Aesthet. Plast. Surg. 2009; 33: 346-52

36. Hasegawa T, Matsukura T, Ikeda S: Mesotherapy for benign symmetric lipomatosis. Aesthet. Plast. Surg. 2010; 34: 153-6

37. Hasengschwandtner F, Gundermann K: Injection lipolysis with phosphatidylcholine and deoxycholate. Aesthet. Surg. J. 2013; 33: 1071-2

38. Hasengschwandtner F: Statistische Auswertung einer Befragung der Ärzte des NETZWERK-Lipolyse. Kosmet. Med. 2013; 34: 29-30

39. Hasengschwandtner F, List P, Spannbauer M: Objektive Messung der Körperzusammensetzung nach Injektionslipolyse mit Polyenylphosphatidylcholin mittels DEXA-Methode (Dual-Energy X-Ray-Absorptiometrie). Kosmet. Med. 2010; #5: 246-52

40. Hasengschwandtner F: Fat melting injections – The latest scientific findings, terms and methods. Kosmet. Med. 2009; #2: 10-5

41. Hasengschwandtner F, Brandl D: Phosphatidylcholine. NETWORK-Lipolysis, 2009, www.network-lipolysis.com/index.php

42. Hasengschwandtner F: Injection lipolysis: a new method of body contouring. In: Handbook of Cosmetic Skin Care – 2nd Edition, e3dt. By A.Shai, H.I.Maibach, R.Baran, Repikla press Pvt Ltd./India, 2009; chapter 13: pp. 102-5

43. Hasengschwandtner F: Altersbedingte Fettgewebsveränderungen: Lipolyse, Cellulitebehandlung. In: Hautalterung – Grundlagen, Prävention, Therapie, edt. By J.Krutmann, T.Diepgen and C.Billmann-Krutmann, Springer press, Heidelberg 2008, chapter 10: pp. 151-165

44. Hasengschwandtner F, Furtmueller F, Spanbauer M, Silye R: Detailed documentation of one lipolysis treatment: blood values, histology, and ultrasound findings. Aesthet. Surg. J. 2007; 27: 204-11

45. Hasengschwandtner F: Injection lipolysis for effective reduction of localized fat in place of minor surgical lipoplasty. Aesthet. Surg. J. 2006; 26: 125-30

46. Hasengschwandtner F: Fat melting injections. Am. J. Mesotherapy 2006; 6: 24-25

47. Hasengschwandtner F: The subcutaneous injection of phosphatidylcholine for means of lipolysis. Lipodissolve – The non surgical liposculpture. Akt. Dermatol. 2005; 31: 549-52

48. Hasengschwandtner F: Phosphatidylcholine treatment to induce lipolysis. J. Cosmet. Dermatol. 2005; 4: 308-13

49. Heinrich K-G: Efficacy of injection of phosphatidylcholine into fat deposits – a non-surgical alternative to liposuction in body-contouring. Indian J. Plast. Surg. 2005; 38: 119-22

50. Heinrich KG: Injection lipolysis with phosphatidylcholine. Cosmet. Med. 2004; #5-6: 238-40

51. Hexsel DM, Serra M, de Oliveira Dal’Forno T, Zechmeister do Prado D: Cosmetic uses of injectable phosphatidylcholine on the face. Otolaryng. Clin. N. Am. 2005; 38: 1119-29

52. Hexsel D, Serra M, Mazzuco R, de Oliveira Dal’Forno T, et al: Phosphatidylcholine in the treatment of localized fat. J. Drugs Dermatol. 2003; 2: 511-8

53. Hoffmann K: Injection lipolysis. Hautarzt 2010; 61: 847-55

54. Hoffmann K, Altmeyer P: Verfahren zur Körperformung. In: Ästhetische und plastische Operationen in der Dermatologie, W3L-press/Herdecke/Witten, 2007; chapter 6.1-6.3

55. Hui KC: Body contouring by liposculpture. The Hong Kong Medical Diary 2008; 13: 20-3

56. Hübner N-F, Horch RE, Polykandriotis E, Rau TT, Dragu A: A histopathologic and immunohistochemical study on liquification of human adipose tissue ex vivo. Aesth. Plast. Surg. 2014; 38: 976-84

57. Hübner NF: Adipocytolyse durch Lipostabil®: Ex vivo Untersuchungen an humane Gewebe (Adipocytolysis by Lipostabil® ex vivo investigations with human tissue). Dissertation July 11, 2012

58. Hunstad JP, De Souza M: Review of “the lipodissolve technique: clinical experience” and author’s comment. Clin. Plast. Surg. 2009; 36: 223-6

59. Hunter NS, El Tawdy AM, Hegazy RA, El Samanoudy SI, et al: Letter: A 15-patient pilot trial of lipolysis of the hips and thighs using a phosphatidylcholine and deoxycholate formulation. Dermatol. Surg. 2013; 39: 791-4

60. Janke J, Engeli S, Gorzelniak K, Luft FC: Compounds used for ‘injection’ lipolysis destroy adipocytes and other cells found in adipose tissue. Obes. Facts 2009; 2: 36-9

61. Kardorff B, Gansel RW, Tats R, Balzer L, et al: 2004 Lipodissolve Clinical Report www.asal-meso.com/html/news/june_1B_2005_news.htm

62. Karolchyk S, Seibert L: Detergent effects of sodium deoxycholate are a major feature of an Injectable phosphatidylcholine formulation used for localized fat dissolution: a review. Am. J. Mesotherapy 2006; 1: 18-9

63. Kato M, Watanabe T, Yamada N, Yoshida Y, et al: Mixed cell granulomatous panniculitis on the cheek due to injection of a solution containing phosphatidylcholine and deoxycholate. Dermatol. Surg. 2010; 36: 1779-81

64. Khan MH, Victor F, Rao B, Sadick NS: Treatment of cellulite – Part II. Advances and controversies. J. Am. Acad. Dermatol. 2010; 62: 373-384

65. Kim HS, Park YM, Kim HO, Lee JY: Intralesional phosphatidylcholine and sodium deoxycholate: a possible treatment option for nevus lipomatosus superficialis. Ped. Dermatol. 2012; 29: 119-21

66. Kirn TF: Injection lipolysis is both defended, criticized: ‘we’ve been using injection lipolysis in my clinic for 2 years now and getting excellent results’. Skin & Allergy News 03/01/08

67. Klein SM, Schreml S, Nerlich M, Prantl L: In vitro studies investigating the effect of subcutaneous phosphatidylcholine injections in the 3T3-L1 adipocyte model: lipolysis or lipid dissolution? Plast. Reconstr. Surg. 2009; 124: 419-27

68. Klein SM, Prantl L, Berner A, Schreml S, et al: A new method to quantify the effect after subcutaneous injection of lipolytic substances. Aesthet. Plast. Surg. 2008; 32: 667-72; discussion 673-4

69. Kopera D, Horejsi R, Werner S, Moeller R: Injektionslipolyse zur Reduktion von seitlich im Bereich des Trochanters gelegenen Fettdepots („Reithosen”) – kontrollierte Halbseiten-Pilotstudie. JDDG 2008; 6: 287-291

70. Kopera D, Binder B, Toplak H, Kerl H, et al: Histopathologic changes after intralesional application of phosphatidylcholine for lipoma reduction – report of a case. Am. J. Dermatopathol. 2006; 28: 331-3

71. Kopera D, Binder B, Toplak H: Intralesional lipolysis with phosphatidylcholine for the treatment of lipomas: pilot study. Arch. Dermatol. 2006; 142: 395-6

72. Kutlubay Z: Evaluation of mesotherapeutic injections of three different combinations of lipolytic agents for body contouring. J. Cosmet. Laser Ther. 2011; 13: 142-53

73. Kyong YY, Choi KH: Woman with hemorrhagic spots on her abdomen. Clin. Toxicol. 2013; 51: 804-5

74. Le Coz J, Rittes PG: Guidelines and limitations on the use of phosphatidylcholine (Lipostabil) in mesotherapy. Am. J. Mesotherapy 2006; 2: 6-7

75. Levy SLJ: Tratamiento de la adiposidad localizada con fosfatidilcolina subcutánea a diferentes concentraciones. Una evaluación histological de su efecto. Dissertation, Mexico October 2013

76. Li H, Lee J-H, Kim SY, Yun H-Y: Phosphatidylcholine induces apoptosis of 3T3-L1 adipocytes. J. Biomed. Sci. 2011; 18: 91

77. Madhère S: Mesotherapy in the management of cellulite. In: Aesthetic Mesotherapy and Injection Lipolysis in Clinical Practice, edt. by S.Madhère, Informa Healthcare Replika press Pvt Ltd./India 2007; chapter 10: 85-98

78. Mahmud K, Crutchfield CE: Lipodissolve for body sculpting - safety, effectiveness, and patient satisfaction. J. Clin. Aesthet. Dermatol. 2012; 5: 16-9

79. Maggiori S: Traitement mésothérapique des xanthelasmas à la phosphatidilcoline polyinsaturée. 5th Cong. Int. Mésothérapie, Paris/France 1988, Oct.07-09, p.364

80. Mann MW, Palm MD, Sengelmann RD: New advances in liposuction technology. Semin. Cutan. Med. Surg. 2008; 27: 72-82

81. Matarasso A, Pfeifer TM: Mesotherapy and injection lipolysis. Clin. Plast. Surg. 2009; 36: 181-92

82. Matarasso A, Pfeifer TM, and the Plastic Surgery Educational Foundation DATA Committee: Mesotherapy for body contouring. Plast. Reconstr. Surg. 2005; 115: 1420-4

83. McNamara D: Lipolysis melts away appearance of double chin. Skin & Allergy News 04/01/09

84. McNamara D: Data validate some lipolysis, but not mesotherapy. Skin & Allergy News 2006; 37: 20

85. McNamara D: Mesotherapy gaining ground as surgery-free fat reducer. Skin & Allergy News 2005; 36: 17

86. Meißner T: Spritze rückt Fettpolstern und Lipomen zu Leibe. Ärzte Zeitung 04.03.2011

87. Mokosch A, Mota R, Gerber PA, Homey B: Severe toxic dermatitis after injection lipolysis. Der Hautarzt 2012; 63: 282-5

88. Môle B: A five years experience of subcutaneous chemical lipolysis with phosphatidylcholine injections. Ann. Chir. PLast. Esthét. 2011; 56: 112-9

89. Motolese P: Phospholipids do not have lipolytic activity. A critical review. J. Cosmet. Laser Ther. 2008; 10: 114-8

90. Myers P: The cosmetic use of phosphatidylcholine in the treatment of localized fat deposits. Cosmet. Dermatol. 2006; 19: 416-20

91. Nanda S: Treatment of lipomas by injection lipolysis. J. Cutan. Aesthet. Surg. 2011; 4: 135-7

92. Noh Y, Heo C-Y: The effect of phosphatidylcholine and deoxycholate compound injections to the localized adipose tissue: an experimental study with a murine model. Arch. Plast. Surg. 2012; 39: 452-6

93. Noreldin AA, Abd Elhamid AM, Hashem AM, Afifi AM: A pilot study on the use of injection lipolysis in visceral adipose tissues. Aesthet. Surg. J. 2013 33: 431-5

94. Olbertz F-W: Injektionslipolyse – ein Erfahrungsbericht nach einjähriger Anwendung. Frauenarzt 2007; 48: 576-7

95. Ono S, Hyakusoka H: Complications after self-injection of hyaluronic acid and phosphatidylcholine for aesthetic purposes. Aesthet. Surg. J. 2010; 30: 442-7

96. Palmer M, Curran J, Bowler P: Clinical experience and safety using phosphatidylcholine injections for the localized reduction of subcutaneous fat: a multicentre, retrospective UK study. J. Cosmet. Dermatol. 2006; 5: 218-26

97. Palumbo P, Melchiorre E, La Torre C, Miconi G, et al: Effects of phosphatidylcholine and sodium deoxycholate on human primary adipocytes and fresh human adipose tissue. Int. J. Immunopath. Pharmacol. 2010; 23: 481-9. Erratum 2010; 23: 970

98. Park E-J, Kim H-S, Kim M, Oh H-J: Histological changes after treatment for localized fat deposits with phosphatidylcholine and sodium deoxycholate. J. Cosmet. Dermatol. 2013; 12: 240-3

99. Peckitt N: Evidenced Based Practice: Phosphatidylcholine – A Review of Evidence for the Mode of Action in Injection Lipolysis. Jeremy Mills Publishing Ltd., Huddersfield, UK, 2005, ISBN: 9781905217137

100. Pindur L, Sand M, Altmeyer P, Bechara FG: Recurrent growth of lipomas after previous treatment with phosphatidylcholine and deoxycholate. J. Cosmet. Laser Ther. 2011; 13: 95-6

101. Rallis E, Kintzoglou S, Moussatoo V, Riga P: Mesotherapy-induced urticaria – Letter to the Editor. Dermatolo. Surg. 2010; 36: 1355-7

102. Reeds DN, Mohammed S, Klein S, Boswell CB, et al: Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet. Surg. J. 2013; 33: 400-8. Comments by Brown SA: Aesthet. Surg. J. 2013; 33: 409-10 & Duncan D: Aesthet. Surg. J. 2013; 33: 411-3

103. Rein P: Injektionslipolyse mit Phosphatidylcholin – Erfahrungen mit der „Fett-Weg-Spritze“. Der Deutsche Dermatologe 2006; #9: 619-20

104. Rey JW, Schreiner O, Barreiros AP, Heise M, et al: Z. Gastroenterol. 2011; 49: 340-3

105. Rha EY, Kang JA, Lee JH, Oh DY, et al: Comparative analysis about the effect of isolated phosphatidylcholine and sodium deoxycholate for the viability of adipocyte. J. Korean Soc. Plast. Reconstr. Surg. 2010; 37: 531-4

106. Rittes PG, Rittes C: Treatment of aging neck with „Lipostabil“ endovena. J. Drugs Dermatol. 2009; 8: 937-9

107. Rittes PG: The lipodissolve technique: clinical experience. Clin. Plast. Surg. 2009; 36: 215-21

108. Rittes PG: Non-surgical body contouring: the Brazilian experience. In: Aesthetic Mesotherapy and Injection Lipolysis in Clinical Practice, edt. by Sh.Madhère, Replika press, Pvt. Ltd./India 2007; chapter 9, pp. 77-83

109. Rittes PG: Complications of Lipostabil endovena for treating localized fat deposits. Aesthet. Surg. J. 2007; 27: 146-9

110. Rittes PG, Rittes J, Amary MFC: Injection of phosphatidylcholine in fat tissue: experimental study of local action in rabbits. Aesthetic Plast. Surg. 2006; 30: 474-8

111. Rittes PG: The use of phosphatidylcholine for correction of localized fat deposits. Am. J. Mesotherapy 2006; 2: 8-11

112. Rittes PG: The use of phosphatidylcholine for correction of localized fat deposits. Aesthetic Plast. Surg. 2003; 27: 315-8

113. Rittes PG: The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. Dermatol. Surg. 2001; 27: 391-2

114. Rose PT, Morgan M: Histological changes associated with mesotherapy for fat dissolution. J. Cosmet. Laser Ther. 2005; 7: 17-9

115. Rotunda AM: Injectable treatments for adipose tissue: terminology, mechanism, and tissue injection. Lasers Surg. Med. 2009; 41: 714-20

116. Rotunda AM: Injectable treatments for adipose tissue: terminology, mechanism, and tissue interaction. Lasers Surg. Med. 2009; 41: 714-20

117. Rotunda AM, Weiss SR, Rivkin LS: Randomized double-blind clinical trial of subcutaneously injected deoxycholate versus a phosphatidylcholine-deoxycholate combination for the reduction of submental fat. Dermatol. Surg. 2009; 35: 792-803

118. Rotunda A: Scientific studies aim to dispel controversy surrounding injection lipolysis. The European Aesthetic Guide Autumn 2008, 74 – 84

119. Rotunda AM: Scientific studies aim to dispel controversy surrounding injection lipolysis. The European Aesthetic Guide, Autumn 2008; 76-84; www.euroabg.com

120. Rotunda AM: Mesotherapy and injection lipolysis. In: Facial Rejuvenation – A Total Approach, edt. by D.J.Goldberg, Springer press Berlin Heidelberg 2007; chapter 7: 147-65

121. Rotunda AM, Kolodney MS: Mesotherapy and phosphatidylcholine injections: historical classification and review. Dermatol. Surg. 2006; 32: 465-80

122. Rotunda AM, Ablon G, Kolodney MS: Lipomas treated with subcutaneous deoxycholate injections. J. Am. Acad. Dermatol. 2005; 53: 973-8

123. Rotunda AM, Avram MM, Avram AS: Cellulite: Is there a role for injectables? J. Cosmet. Laser Ther. 2005; 7: 147-54

124. Rotunda AM, Suzuki H, Moy RL, Kolodney MS: Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol. Surg. 2004; 30: 1001-8

125. Salles AG, Valler CS, Ferreira MC: Histologic response to injected phosphatidylcholine in fat tissue: experimental study in a new rabbit model. Aesthet. Plast. Surg. 2006; 30: 479-84

126. Salti G, Ghersetich I, Tantussi F, Bovani B et al: Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study. Dermatol. Surg. 2008; 34: 60-6

127. Salti G, Rauso R: Comments on “Injection Lipolysis with phosphatidylcholine and deoxycholate”. Aesthet. Surg. J. 2014; 34: 639-40

128. Schuller-Petrovic S, Wölkart G, Höfler G, Neuhold N, et al: Tissue-toxic effects of phosphatidylcholine/deoxycholate after subcutaneous injection for fat dissolution in rats and a human volunteer. Dermatol. Surg. 2008; 34: 529-43

129. Sobel HD: Editorial – Off-label usage of medical devices. Int. J. Cosm. Surg. Aesthet. Dermatol. 2002; 4: 259

130. Steinert M: Injektionslipolyse. DERMAforum 2009; #1: 4

131. Strahan JE, Cohen JL, Chorny JA: Granuloma annulare as a complication of mesotherapy: a case report. Dermatol. Surg. 2008; 34: 836-8

132. Tanner B, Barabas T, Crook D, Link C: A future for injection lipolysis. Aesthet. Surg. J. 2013; 33: 456-7

133. Tawfik HA, Zuel-Fakkar NMA, Wlmarasy R, Talib N, et al: Phosphatidylcholine for the treatment of prominent lower eyelid fat pads: a pilot study. Ophthal. Plast. Reconstr. Surg. 2011; 27: 147-51

134. Toledo LS: a) Preface b) Emerging techniques in aesthetic plastic surgery. Clin. Plast. Surg. 2009; 36: a) xi-xiii b) 177-80

135. Treacy PJ, Goldberg DJ: Use of phosphatidylcholine for the correction of lower lid bulging due to prominent fad pads. J. Cosmet. Laser Ther. 2006; 8: 129-32

136. Uygur F, Evinç R, Duman H: Is phosphatidylcholine harmful to the peripheral neural tissue? An experimental study in rats. Aesthet. J. Surg. 2008; 28: 663-7

137. Walsh N: Some would halt lipolysis Tx pending safety data. Skin & Allergy News 2004; 35: 26

138. Weiss DD, Carraway JH: Eyelid rejuvenation: a marriage of old and new. Curr. Opin. Otolaryngol. Head Neck Surg. 2005; 13: 248-54

139. Witort EJ, Pattarino J, Romano FM, Dini M, et al: Lipolytic effectiveness of phosphatidylcholine in the treatment of ‘buffalo hump’ of HIV patients. J. Plast. Reconstr. Aesthet. Surg. 2011; 64: e26-8

140. Won TJ, Nam Y, Lee HS, Chung S, et al: Injection of phosphatidylcholine and deoxycholic acid regulates gene expression of lipolysis-related factors, pro-inflammatory cytokines, and hormones on mouse fat tissue. Food Chem. Toxicol. 2013; 60: 263-8

141. Wong GR, Chen W-P: Phosphatidylcholine/deoxycholate lipolysis and hyaluronic acid augmentation to enhance nonsurgical lower facial contouring using botulinum toxin type A. J. Cosmet. Dermatol. 2011; 10: 159-62

142. Worcester S: Lipodissolve mesotherapy is gaining popularity. Skin & Allergy News 2007; 38: 25

143. Young VL: Letter to the editor – Response to “injection lipolysis with phosphatidylcholine and deoxycholate”. Aesthet. Surg. J. 2013; 33: 1076

144. Young VL: Lipostabil: the effect of phosphatidylcholine on subcutaneous fat. Aesthet. Surg. J. 2003; 23: 413-7

145. Zhang Y, Gao J-h, Jiang P, Wang L-y, et al: Chin. J. Aesthet. Med. 2006; 15: 1346-8

 

Referenzliste Phosphatidylcholin 1

1. Parnham MJ, Wendel A. Phospholipids and liposomes - safety for cosmetical and pharmaceutical use. Nattermann Phospholipid GMBH Scientific Publication no. 1995432003, 2. Cologne, West Germany: Nattermann International GMBH.

Dazugehörige Referenzen:
- Bergenstahl, B. (1990). Phase diagrams of mixed soybean phospholipids. In: Food Polymers, Gels and Colloids, edited by E. Dickinson, Royal Society of Chemistry, London, pp. 123-131.
- De Vleeschauwer, D., Van der Meeren, P. & Vanderdeelen, J. (1996). Influence of electrolytes on phospholipid-stabilised emulsions. Bulletins des Societes Chimiques Belges, 105, 809-814.
- De Vleeschauwer, D. & Van der Meeren, P. (1999). Colloid chemical stability and interfacial properties of mixed phospholipid-nonionic surfactant stabilised oil-in-water emulsions. Colloids and Surfaces A 152, 59-66.
- Friberg, S.E. & Solans, C. (1986). Surfactant association structures and the stability of emulsions and foams. Langmuir, 2, 121-126.
- Hofman, J.A.M.H. & Stein, H.N. (1991). Destabilization of emulsions through deformation of the droplets. J. Colloid Interface Sci. 147, 508-516.
- Kaufmann, P., Olsson, O. & Herslof, B.G. (1990). A chemometric strategy for the classification of lecithins according to process performance. J. Am. Oil Chem. Soc. 67, 537-540.
- Pardun, H. (1989). Vegetable lecithins - valuable auxiliary and active substances? Fat Sci. Technol. 91, 45-58.
- Rydhag, L. (1979). The importance of the phase behaviour of phospholipids for emulsion stability. Fette, Seifen, Anstrichmittel 81, 168-173.
- Rydhag, L. & Wilton, I. (1981). The function of phospholipids of soybean lecithin in emulsions. J. Am. Oil Chem. Soc. 58, 830-837.
- Szuhaj, B.F. (1989). Lecithins : sources, manufacture & uses, The American Oil Chemists' Society, Champaign, Illinois, 283 p.
- Van der Meeren, P., Stastny, M., Vanderdeelen, J. & Baert, L. (1995a). Functional properties of purified soybean lecithins in O/W emulsions. In: G. Cevc and F. Paltauf (Eds.).
- Phospholipids: characterisation, metabolism and novel biological applications. AOCS Press, Champaign, USA, p.111-119.
- Van der Meeren, P., Vanderdeelen, J. & Baert, L. (1995b). On the relationship between dynamic interfacial tension and O/W emulsion stabilizing properties of soybean lecithins.
Progr. Colloid Polym. Sci. 98, 136-139.
- Van Nieuwenhuyzen, W. (1997). Functionality of lecithins. Fett/Lipid, 99, 10-14.
2. Lipostabil (package insert). Frankfurt: Aventis Pharma, 2003.
3. Essentiale (package insert). Frankfurt: Aventis Pharma, 2003.
4. How do lecithins work? Learn about lecithins (Internet). Oxford (CT): American Lecithin Company, 2003. Available from: www.americanlecithin.com/lecithin.pdf
5. Lipostabil. Natterman International GMBH. Cologne, Germany: Natterman International, 1990:9.
6. Durr M, Hager J, Lohr JP. Investigation on mixed micelle and liposome preparations for parental use on soya phosphatidylcholine. Eur J Pharm Biopharm 1994;40: 147-56.
7. Lichtenberg D, Zilberman Y, Greenzaid P, Zamir S. Structural and kinetic studies on the solubilization of lecithin by sodium deoxycholate. Biochemistry 1979;18: 3517-25.
8. Lichtenberg D, Robson RJ, Dennis EA. Solubilization of phospholipids by detergents: structural and kinetic aspects. Biochim Biophys Acta 1983;737: 285-304.
9. Teelmann K, Schlappi B, Schupbach M, Kistler A. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneimittelforschung 1984;34: 1517-23.
10. Hammad MA, Muller BW. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm 1998;46: 361-7.
11. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of Taxol. Pharm Res 1994, 2003;11: 206-12.
12. Basic Phlebology Primer (Internet). Oakland (CA): American College of Phlebology, c1998. Available from: www.phlebology.org/topics.htm
13. Vlahcevic ZR, Heuman DM. Diseases of the gall bladder and bile ducts. In: Goldman L, Bennet JC, Cecil R, eds. Cecil Textbook of Medicine. St. Louis (MO): Saunders, 2001: 822-4.
14. Womack MD, Kendall DA, MacDonald RC. Detergent effects on enzyme activity and solubilization of lipid bilayer membranes. Biochim Biophys Acta 1983;733: 210-5.
15. Lichtenberg D. Characterization of the solubilization of lipid bilayers by surfactants. Biochim Biophys Acta 1985;821: 470-8.
16. Banerjee P, Joo JB, Buse JT, Dawson G. Differential solubilization of lipids along with membrane proteins by different classes of detergents. Chem Phys Lipids 1995;77: 65-78
17. Almgren M. Mixed micelles and other structures in the solubilization of bilayer lipid membranes by surfactants. Biochim Biophys Acta 2000;1508: 146-63.
18. Schuck S, Honsho M, Ekroos K, Shevchenko A, Simons K. Resistance of cell membranes to different detergents. Proc Natl Acad Sci USA 2003;100: 5795-800.
19. Heerklotz H, Seelig J. Correlation of membrane/water partition coefficients of detergents with the critical micelle concentration. Biophys J 2000;78: 2435-40.
20. Canty D, Zeisel S, Jolitz A. Lecithin and Choline: Research Update on Health and Nutrition. Fort Wayne (IN): Central Soya Company, 1996.
21. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994;106: 152-9.
22. Lieber CS, DeCarli LM. Animal models of chronic ethanol toxicity. Methods Enzymol 1994;233: 585-94.
23. Buko V, Lukivskaya O, Nikitin V, et al. Hepatic and pancreatic effects of
polyenoylphosphatidylcholine in rats with alloxan-induced diabetes. Cell Biochem Funct 1996;14: 131-7.
24. Jones MN. Surfactants in membrane solubilisation. Int J Pharm 1999;177: 137-59.
25. Gustafson C, Tagesson C. Influence of organic solvent mixtures on biological membranes. Br J Ind Med 1985;42: 591-5.
26. Lester DS, Baumann D. Action of organic solvents on protein kinase C. Eur J Pharmacol 1991;206: 301-8.
27. Engelke M, Jessel R, Wiechmann A, Diehl HA. Effect of inhalation anaesthetics on the phase behaviour, permeability and order of phosphatidylcholine bilayers. Biophys Chem 1997;67: 127- 38.
28. Ebihara L, Hall JE, MacDonald RC, McIntosh TJ, Simon SA. Effect of benzyl alcohol on lipid bilayers: a comparisons of bilayer systems. Biophys J 1979;28: 185-96.
29. Gordon LM, Sauerheber RD, Esgate JA, et al. The increase in bilayer fluidity of rat liver plasma membranes achieved by the local anesthetic benzyl alcohol affects the activity of intrinsic membrane enzymes. J Biol Chem 1980;255: 4519-27.
30. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972;175: 720-31.
31. Christie,W.W. : Lipid Analysis – 3.Auflage ( Oily Press, Bridgewater 2003 )
32. Vance, D.E. and Vance J. : Biochemistry of Lipids, Lipoproteids and Membranes ( Elsevier, Amsterdam -2004 )
33. Veldhuizen R., Nag K., Orgeig S. Possmeayer F.: The role of Lipids in pulmonary surfactant (Biochim.Biophys. Acta 1408. 90-108 (1998)
34. Xu Y., Spingosynphosphorylcholine and lysophosphatidylcholine, G.protein-coupled redeptors and receptor-mediated signal transduction. ( Biochim.Biophys. Acta 1582, 81-88 2004)
35. Kidd, PM.: Dietary phospholipids as anti-aging nutraceuticals
36. Klatz RA, Goldman R, eds. Anti Aging Medical Therapeutics, Chicago, Health Quest Publications 2000:283-301 47.
37. NY:Marcel Dekker;1997:15-30, Kent C.: Eukaryotic phospholipids biosynthesis. Annu Rev. Biochem 1995; 64:315-343
38. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. Lipid Technologies and Applications.
39. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995;64:315-343.
40. Zierenberg 0, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 1982;23:1136-1142
41. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. Altern Med Rev 1996;1:148-167.
42. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. Altern Med Rev 1996;1:258-274.
43. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB 1991;5:2093-2098.
44. Wurtman RJ , Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. Lancet 1977;ii: 68-69.
45. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995;22:1399-1403.
46. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. Clin Res 1968;16:450.
47. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. Lancet 1975;ii: 1124-1126.
48. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. Early Human Dev 1999;54:157-168.
49. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol 1993;28:89-94.
50. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatedylcholine in comparison with placebo in the case of alcoholic liver steatosis. Med Welt 1985;72:517~521.
51. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 92;102:1363-1370.
52. Panos MZ, PoIson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp*lipid Research (EPL). Bingin-Rhein, Germany: wbn- Verlag; 1990: 103-110.
53. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77- 81
54. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. La Clinica Terapeutica 1985;114:183-188
55. Ilic V, Hegic-Janev A. Therapy for HHsAg-positive chronically active hepatitis. MedWelt 1991;42:523- 525.
56. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and
57. interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo controlled trial. Hepatogastroenterol 1998;45:797-804
58. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? Alcoholism Clin Exp Res 1994;18:1286-1288.
59. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51:226-;237.
60. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non- steroidal anti-I inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). Eur J PharmacoI1985;117:35 -42.
61. Swarm RA, Ashley SW, Soybel Dl, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. Am J Surg 1987;153:48-53.
62. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr Res 1998;44:491-495.
63. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.
64. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high- dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatr 1985;48:736-742.
65. Esslinger F. Death cap mushroom poisoning: report of clinical experience. Med Welt 1966;19:1057-1063.
66. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev. 1994; 52:327-339.
67. Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. Clin Psychiatry. 1990; 51:149-153.
68. Growdon JH, Gelenberg AJ, Doller J, et al. Lecithin can suppress tardive dyskinesia. N Engl JMed. 1978; 298:1029-1030.
69. Hanin I, Ansell GB, eds. Lecithin. Technological, Biological and Therapeutic Aspects. New York and London: Plenum Press; 1987.
70. KLEMM J, PABST HW. Untersuchungen to uber den Einfluss to therapeutischer Teilkoerperbestrahlungen auf die Leberfunktion und die Schutzwirkung to essentieller Phospholipide. Strahlentherapie 1964;123:438-450. [In German, summary in English]
71. KNUECHEL F. Double blind study in patients with alcohol-toxic fatty to liver. Med Welt 1979;30:411-416.
72. KOSINA F, BUDKA K, KOLOUCH Z, et al. Viral Essential cholinephospholipids in the treatment of hepatitis. Cas Lek Ces 1981;120:957-960.
73. KUNTZ HD, RAUSCH V, BAMMER And "essential" Hepatotoxicity of rifampicin and the effect thereon of choline phospholipids. Med Welt 1978;29:452-454.
74. MUETING D, DOHN P, REIKOWSKI J. essential Effect of high doses of phospholipids administered intravenously and perorally on metabolism of albumin and fats and on enzymatic activity of chronically ill to liver patients. Verhandlungen der Deutsche Gesellschaft fur Innere Medizin 1972;17:1389-1392.
75. PANOZ MZ, POLSON R, JOHNSON R, ET AL. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic activates hepatitis hepatitis and in acute alcoholic. In: Gundermann K, Schumacher R, eds. 50th Anniversary of Phospholipid Research (EPL) International Symposium. Bingen/Rhein: wbn-Verlag;1990.
76. SCHULLER PEREZ, SAN MARTIN F.G. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the marries of alcoholic to liver steatosis. Med Welt 1985;72:517-521.
77. SIMONSSON P, NILSSON, AKESSON B Postprandial effects of dietary phosphatidylcholine on plasma lipoproteins in man. Am J Clin Nutr 1982 Jan;35(1):36-41
78. SORRENTINO F, DIENE G, CORVAJA and, et al. Polyunsaturated uses of phosphatidylcholine (EPL) in association with vitamin B complex in to liver therapy. La Clinica Terapeutica 1982;102:163-183.
79. VISCO G. Polyunsaturated phosphatidylcholine associated with vitamin B complex in the treatment of acute viral hepatitis B. La Clinica Terapeutica 1985;114:183-188.
80. WALLNOEFER H, HANUSCH M. "Essential" phospholipids in the treatment of hepatic disease. Med Monatsschrift 1973;27:131-136.
81. YANO M, KOGA M, SHIRAHAMA S, et al. Blind assessment of liver biopsy findings in chronic hepatitis: drug efficacy trial of polyene phosphatidylcholine. Shindan to chiryo 1978;9:1783-1789.
82. MEL'CHINSKAIA EN, GROMNATSKII NI, KIRICHENKO LL [ lipostabil Hypolipidemic effects of alisat and in patients with diabetes mellitus]. To have Arkh 2000;72(8):57-8 [Article in Russian, with summary in English]
83. ZEMAN M, ZAK A, STOLBA P [The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB]. Sb Lek 1995;96(1):43-8.
84. WAREMBOURG H, JAILLARD J. Experimentation clinique du lipostabil dans le traitement des angiopathies diabetiques. Lille Med 1968; XIII (suppl):721-3.

 

Referenzliste Phospatidylcholin 2

2. Kidd PM. Dietary phospholipids as anti-aging nutraceuticals. In: Klatz RA, Goldman R, eds. Anti-Aging Medical Therapeutics. Chicago, IL: Health Quest Publications; 2000:283-301.
3. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr 1994;14:269-296.
4. Brook, JG, Linn, S, and Aviram, M. Biochem Med Metabol Biol. 35;31-39, 1986.
5. Canty, DJ and Zeisel, SH. Nutr Reviews. 52;327-339, 1994;
6. Zeisel, SH, et al. Faseb J Nutr Reviews 5;2093-2098, 1991
8. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. Lipid Technologies and Applications. New York, NY: Marcel Dekker; 1997:15-30.
9. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995;64:315-343.
10. Zierenberg 0, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 1982;23:1136-1142.
11. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. Altern Med Rev 1996;1:148-167.
12. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. Altern Med Rev 1996;1:258-274.
13. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB 1991;5:2093-2098.
14. Wurtman RJ , Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. Lancet 1977;ii: 68-69.
15. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995;22:1399-1403.
16. Ghyczy M, Boros M. Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. Brit J Nutr 2001;85:409-414.
17. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. Clin Res 1968;16:450.
18. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. Lancet 1975;ii: 1124-1126.
19. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. Early Human Dev 1999;54:157-168.
20. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol 1993;28:89-94.
21. Lieber CS, Leo MA. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcoholism Clin Exp Res 1997;21:375-379.
22. Knuchel F. Double blind study in patients with alcohol-toxic fatty liver. Med Welt 1979;30:411-416.
23. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. Med Welt 1985;72:517~521.
24. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-1370.
25. Panos MZ, PoIson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp*lipid Research (EPL). Bingin-Rhein, Germany: wbn- Verlag; 1990: 103-110.
26. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994;106:152-159.
27. Marpaung H, Tarigan P, Zein LH, et al. Tuberkulostatische kombinations therapie aus INH, RMP und EMH. Therapiewoche 1988;38:734- 740.
28. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77- 81.
29. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. La Clinica Terapeutica 1985;114:183-188.
30. Ilic V, Hegic-Janev A. Therapy for HHsAg-positive chronically active hepatitis. MedWelt 1991;42:523-525.
31. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo-controlled trial. Hepatogastroenterol 1998;45:797-804.
32. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? Alcoholism Clin Exp Res 1994;18:1286-1288.
33. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51 :226-;237.
34. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non- steroidal anti-inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). Eur J PharmacoI1985;117:35-42.
35. Swarm RA, Ashley SW, Soybel Dl, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. Am J Surg 1987;153:48-53.
36. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr Res 1998;44:491-495.
37. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.
38. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high- dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatr 1985;48:736-742.
39. Esslinger F. Death cap mushroom poisoning: report of clinical experience. Med Welt 1966;19:1057-1063.
40. Kidd PM. Dietary phospholipids as anti-aging nutraceuticals. In: Klatz RA, Goldman R, eds. Anti-Aging Medical Therapeutics. Chicago, IL: Health Quest Publications; 2000:283-301.
41. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr 1994;14:269-296.
42. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. Lipid Technologies and Applications. New York, NY: Marcel Dekker; 1997:15-30.
43. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995;64:315-343.
44. Zierenberg 0, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 1982;23:1136-1142.
45. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. Altern Med Rev 1996;1:148-167.
46. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. Altern Med Rev 1996;1:258-274.
47. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB 1991;5:2093-2098.
48. Wurtman RJ , Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. Lancet 1977;ii: 68-69.
49. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995;22:1399-1403.
50. Ghyczy M, Boros M. Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. Brit J Nutr 2001;85:409-414.
51. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. Clin Res 1968;16:450.
52. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. Lancet 1975;ii: 1124-1126.
53. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. Early Human Dev 1999;54:157-168.
54. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol 1993;28:89-94.
55. Lieber CS, Leo MA. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcoholism Clin Exp Res 1997;21:375-379.
56. Knuchel F. Double blind study in patients with alcohol-toxic fatty liver. Med Welt 1979;30:411-416.
57. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. Med Welt 1985;72:517~521.
58. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-1370.
59. Panos MZ, PoIson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp*lipid Research (EPL). Bingin-Rhein, Germany: wbn- Verlag; 1990: 103-110.
60. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994;106:152-159.
61. Marpaung H, Tarigan P, Zein LH, et al. Tuberkulostatische kombinations therapie aus INH, RMP und EMH. Therapiewoche 1988;38:734- 740.
62. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77- 81.
63. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. La Clinica Terapeutica 1985;114:183-188.
64. Ilic V, Hegic-Janev A. Therapy for HHsAg-positive chronically active hepatitis. MedWelt 1991;42:523-525.
65. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo-controlled trial. Hepatogastroenterol 1998;45:797-804.
66. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? Alcoholism Clin Exp Res 1994;18:1286-1288.
67. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51 :226-;237.
68. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non- steroidal anti-inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). Eur J PharmacoI1985;117:35-42.
69. Swarm RA, Ashley SW, Soybel Dl, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. Am J Surg 1987;153:48-53.
70. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr Res 1998;44:491-495.
71. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.
72. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high- dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatr 1985;48:736-742.
73. Esslinger F. Death cap mushroom poisoning: report of clinical experience. Med Welt 1966;19:1057-1063.
74. Alberts B, Bray D, Lewis L, et al. Molecular Biology of The Cell. New York:Garland Publishing;1989.
75. Jones AL. Anatomy of the normal liver. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia:WB Saunders; 1996:3-32.
76. Kuntz E. Pilot study with polyenylphosphatidylcholine in severe liver insufficiency. Med Welt 1989;40:1327-1329.
77. Kidd PM. Liver biotransformation of xenobiotic chemicals, foods, and drugs to free radical oxidants. In: Levine S, Kidd PM. Antioxidant AdaptationÑIts Role in Free Radical Pathology. San Leandro, California:Biocurrents;1985: 221-281.
78. Fausto N. Hepatic regeneration. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia:WB Saunders;1996:32-58.
79. Wallnoefer H, Hanusch M. "Essential" phospholipids in the treatment of hepatic disease. Med Monatsschrift 1973;27:131-136.
80. Friedman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease. Philadelphia:WB Saunders;1996:791-833.
81. Sorrentino F, Diene G, Corvaja E, et al. Use of polyunsaturated phosphatidylcholine (EPL) in association with vitamin B complex in liver therapy. La Clinica Terapeutica 1982;102:163-183.
82. Lieber CS. alcohol and the liver:1994 update. Gastroenterology 1994;106:1085-1105.
83. Lieber CS. Alcohol-induced liver disease. In: Maddrey WC, ed. Gastroenterology and Hepatology: The Comprehensive Visual Reference. Philadelphia: Current Medicine; 1996:9.1-9.21.
84. Knuechel F. Double blind study in patients with alcohol-toxic fatty liver. Med Welt 1979;30:411-416.
85. Schuller Perez A, San Martin F.G. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis.Med Welt 1985;72:517-521.
86. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-1370.
87. Panoz MZ, Polson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann K, Schumacher R, eds. 50th Anniversary of Phospholipid Research (EPL) International Symposium. Bingen/Rhein: wbn-Verlag;1990.
88. Lieber CS ; DeCarli LM ; Mak KM ; Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 1990;12:1390-1398.
89. Li J, Kim C, Leo MA, et al. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1991;15:373-381.
90. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 1994;106:152-159.
91. Schenker S, Hoyumpa AM. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? Alcoholism: Clin Exp Res 1994;18:1286-1288.
92. Hoyumpa AM, Schenker S. Drugs and the liver. In: Maddrey WC, ed. Gastroenterology and Hepatology: The Comprehensive Visual Reference. Philadelphia: Current Medicine; 1996:6.1-6.22.
93. www.thorne.com/altmedrev/fulltext/phos1-4.html (21 of 24)26/04/2005 11:28:54 Phosphatidylcholine
94. Marpaung B, Tarigan P, Zein LH, et al. Tuberkulostatische KombinationsÑtherapie aus INH, RMP und EMB. Therapiewoche 1988;38:734-740.
95. Kuntz HD, Rausch V, Bammer E. Hepatotoxicity of rifampicin and the effect thereon of "essential" choline phospholipids. Med Welt 1978;29:452-454.
96. Hisanaga M, Utsumi S, Miyamoto S, et al. Abnormality of liver function in patients treated with antiepileptic drug and a trial of polyene phosphatidylcholine treatment for these patients. Folia Psychiatr Neurol Japonica 1980;34:318-319.
97. Kuntz E, Neumann-Mangold P. Acute peroral trichloroethylene poisoning. Med Welt 1965;16:2872-2874.
98. Esslinger F. Death cap mushroom poisoning: report of clinical experience. Med Welt 1966;19:1057-1063.
99. Klemm J, Pabst HW. Untersuchungen uber den Einfluss therapeutischer Teilkoerperbestrahlungen auf die Leberfunktion und die Schutzwirkung essentieller Phospholipide. Strahlentherapie 1964;123:438-450. [In German, summary in English]
100. Mueting D, Dohn P, Reikowski J. Effect of high doses of essential phospholipids administered intravenously and perorally on metabolism of albumin and fats and on enzymatic activity of chronically ill liver patients. Verhandlungen der Deutsche Gesselchaft fur Innere Medizin 1972;17:1389-1392.
101. Hirayama C, Okamura M, Tanikawa K, et al. The clinical effect of polyene phosphatidylcholine in chronic hepatitis in a double-blind test. Rinsho to kenkyu 1978;55:194-198.
102. Yano M, Koga M, Shirahama S, et al. Blind assessment of liver biopsy findings in chronic hepatitis: drug efficacy trial of polyene phosphatidylcholine. Shindan to chiryo 1978;9:1783-1789.
103. Kosina F, Budka K, Kolouch Z, et al. Essential cholinephospholipids in the treatment of viral hepatitis. Cas Lek Ces 1981;120:957-960.
104. Jenkins PJ, Portmann BP, Eddleston ALWF, et al. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77-81.
105. Visco G. Polyunsaturated phosphatidylcholine associated with vitamin B complex in the treatment of acute viral hepatitis B. La Clinica Terapeutica 1985;114:183-188.
106. Hantak I, Boca M, Miculecky M, et al. Essential phospholipids in the treatment of chronic infection with the hepatitis B virus. Vnitrni Lekarstvi 1990;36:1164-1171.
107. Fassati P, Horesji J, Fassati M, et al. The effect of choline phospholipids on HBsAg and selected biochemistry tests in cirrhosis of the liver. Cas Lek Ces 1981;120:56-60.
108. Ilic V, Begic-Janev A. Therapy for HBsAg-positive chronically active hepatitis. Effect of "essential' phospholipids. Med Welt 1991;85:523-525.
109. Kalab M, Cervinka J. Essential phospholipids in the treatment of cirrhosis of the liver. Cas Lek Ces 1983;122:266-269. [In Slovak, with English summary]
110. Docker O. Therapy of chronic liver diseases and acute, life-threatening liver failure conditions. Med Welt 1960;20:1079-84.
111. Frosch B, Wagener H. Therapy of hepatitis epidemica. Fortschritte Med 1963;81:725-7.
112. Kautsch E. Comparison of therapy in acute hepatitis epidemica. Med Klinische 1965;60:1401-1410.
113. Rottini E, Bazzanella F, Marri DG, et al. Therapy of different types of liver insufficiency using "Essential" phospholipids. Med Monatsschrift 1963;17:28-30.
114. Wegner H. Essential phospholipids in the therapy of hepatitis infectiosa. Munch Med Welt 1965;5:227-231.
115. Cullis PR. Phospholipids and membrane transport. Can J Biochem 1980; 58, 1091-1095.
116. Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. Science 1980;209:1082-1083.
117. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985;26:1015-1035.
118. Shinitzky M. Membrane fluidity and receptor function. In: Kates M, Manson LA, eds. Membrane Fluidity. New York:Plenum Press; 1984.
119. Kidd PM. Cell membranes, endothelia, and atherosclerosisÑthe importance of dietary fatty acid balance. Alternative Medicine Review 1996; 1(3): 148-167.
120. Fox JM, et al. Pharmacokinetics of orally ingested phosphatidylcholine. In: Barbeau A, et al, eds. Nutrition and the Brain, Volume 5. New York: Raven Press; 1979:95-108.
121. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB 1016) in chronic active hepatitis. Intl J Clin Pharmacol Ther Toxicol 1993; 31:456-460.
122. Lieber CS, Leo MA, Mak KM, et al. Choline fails to prevent liver fibrosis in ethanolfed baboons but causes toxicity. Hepatology 1985; 5:561-572.
123. Lipostabil. Natterman International GMBH,1990;
124. Wojcicki, J, et al. Phytotherapy Res. 9;597-599, 1995)
125. Wutman, R, et al. Nutrition and the Brain. Vol. 5. Raven Press: New York, 1979; Cohen, B, et al. Am J Psychiat 137:242-243, 1980
126. Cohen, B, et al. Am J Psychiat 139;1162-1164, 1982.
127. Jope, R, et al. Am J Psychiat 142;356-358,1985
128. Rosenberg, G and Davis, KL. Am J Clin Nutr. 36; 709-720, 1982;
129. Levy, R, et al. Lancet 1;474-476,1982;
130. Sitaram, N, et al. Life Sci 22;1555-1560, 1978.
131. Daily, JW and Sachan, DS. J Nutr 125;1938-1944, 1995
132. Varela-Mreiras, G, et al. J Nutr Biochem 3;519-522, 1992.
134. Singer, S.J.; Nicolson, G.L. Science. 1972, 175, 723-731.
136. Phosphatidylcholine in the treatment of localized fat. Journal of Drugs in Dermatology Oct, 2003; Hexsel D, Serra M, Mazzuco R, Dal'Forno T, Zechmeister D.
137. Adams, J. M. & Cory, S. (2001). Life-or-death decisions by the Bcl-2 protein family. TIBS 26: 61-66. Science Direct
138. Adrain, C. & Martin, S. J. (2001). The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. TIBS 26: 390-397. Science Direct
139. Bortner, C. D. & Cidlowski, J. A. (2002). Cellular Mechanisms for the repression of apoptosis. Annu. Rev. Pharmacol. Toxicol. 42: 259-281. PubMed
140. Cory, S. & Adams, J. M. (2002). The Bcl2 family: Regulators of the cellular life-or-death switch. Nature Reviews Cancer 2: 647-656. PubMed
141. Curtin, J. F. & Cotter, T. G. (2003). Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cellular Signalling 15: 983-992.Science Direct
142. Desagher, S. & Martinou, J.-C. (2000). Mitochondria as the central control point of apoptosis. Trends in Cell Biology 10:369-377. Science Direct
143. Dumont, E. A. et al. (2001). Real time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nature Medicine 7: 1352-1355. PubMed
144. Franke, T. F. (2002). Survival signalling by phosphorylation: PI3K/Akt sets the stage. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 235-261. Oxford University Press. OUP
145. Gervais, F. G. et al. (2002). Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology 4: 95-105. PubMed
146. Gill, C. et al. (2002). Losing heart: the role of apoptosis in heart disease - a novel therapeutic target? FASEB J 16: 135-146. PubMed
147. Gottlieb, R. A. & Kitsis, R. N. (2001). Seeing death in the living. Nature Medicine 7: 1277-1278. PubMed
148. Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature 407: 770-776. PubMed
149. Huang, P. & Oliff, A. (2001). Signaling pathways in apoptosis as potential targets for cancer therapy. Trends in Cell Biology 11: 343-348.Science Direct
150. Igney, F. H. & Krammer, P. H. (2002). Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer 2: 277-288. PubMed
151. Jacobson, M. D. & Bergeron, L. (2002). Cell death in the nervous system. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 278-300. Oxford University Press. OUP
152. Kauffmann, S. H. & Hengartner, M. O. (2001). Programmed cell death: alive and well in the new millennium. Trends in Cell Biology 11: 526-534. Science Direct
153. Krammer, P. H. (2000). CD95's deadly mission in the immune system. Nature 407: 789-795. PubMed
154. Lam, M. et al. (2001). Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. J. Biol. Chem. 276: 47379-47386. PubMed
155. McCarthy, N. & Bennett, M. R. (2002). Death signalling by the CD95/TNFR family of death domain-containing receptors. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 200-234. Oxford University Press. OUP
156. Nicholson, D. W. (2000). From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810-816. PubMed
157. Pope, R. M (2002). Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Reviews Immunology 2:1-9. Nature
158. Roy, N. & Cardone, M. H. (2002). The caspases: consequential cleavage. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 93-135. Oxford University Press. OUP
159. Strasser, A. et al. (2000). Apoptosis signaling. Annu. Rev. Biochem. 69: 217-245. PubMed
160. Tentori, L. et al. (2002). Potential clinical applications of Poly (ADP-Ribose) Polymerase (PARP) inhibitors. Pharmacological Research 45: 73-85. Science Direct
161. Tsujimoto, Y. (2002). Regulation of apoptosis by the Bcl-2 family of proteins. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 136-160. Oxford University Press. OUP
162. Vousden, K. H. & Lu, X. (2002). Live or let die: the cell's response to p53. Nature Reviews Cancer 2: 594-604. PubMed
163. Xue, D et al. (2002). Programmed cell death in C. elegans: the genetic framework. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 23-55. Oxford University Press. OUP
164. Yu et al. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263. PubMed
165. Yuan, J. & Yankner, B. A. (2000). Apoptosis in the nervous system. Nature 407: 802-809. PubMed
166. Zamzami, N. et al. (2002). Mitochondria in apoptosis: Pandora's box. In Apoptosis: the molecular biology of programmed cell death ed. Jacobson, M. D. & McCarthy, N. pp 161-175. Oxford University Press. OUP

 



EnglishOther
Language


Artikel von Dr. Hasengschwandtner in Gesundheit.com zum Downloaden

   128 K

Nachweis der Fettzellauflösung

Die Plastischen Chirurgen der Universität Regensburg haben die Fettpolster von New Zealand Kaninchen mit den Wirkstoffen PPC-DOC behandelt. Die Ergebnisse wurden mit einem 3D Ultraschall gemessen:




Vorher 15.62 cm3




Nach 10 Tagen 12.94 cm3




Nach 21 Tagen 8.31 cm3

   © 2004-2016 by Lichtblick GmbH    Impressum